



## BIOEUROPE SPRING

F.R. Martelet, M.D., CEO

*22 – 25 March 2021*

# Forward-looking statement

## **IMPORTANT NOTICE**

*The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.*

*No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.*

*The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.*


## **FORWARD LOOKING STATEMENTS**

*This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Oasmia believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.*

*Important factors that may cause such a difference for Oasmia include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.*

*This presentation does not imply that Oasmia has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.*

# Oasmia – an innovation-focused specialty pharmaceutical company




Growing pipeline, focused on **Oncology** and with potential in other therapeutic areas



**XR-17™ technology platform** to enhance intravenous delivery of established and novel drugs in diseases including cancer



**Global partnering deal** for Apealea® in ovarian cancer worth up to **\$698m**



Significant **in-/out-licensing & M&A** opportunities to drive growth



**Lean and agile**  
Solid cash position



**Clear strategy** driven by new leadership team

# A clearly defined strategy to support future growth

1

## Execute on Apealea® global partnership with Elevar

- US regulatory pathway identified by Elevar
- Commercialization deals signed for Europe, MENA
- Global Named Patient program launched
- Planned commercial partnerships in Asia & LatAm

2

## Enhancement & partnering of technology platforms

- Work underway to potentially enhance XR-17™
- Additional platforms in development incl. for combination therapy
- Increased focus on partnering to leverage proven R&D and regulatory skills

3

## Clinical development of Docetaxel micellar

- Ready to enter Phase 1b in prostate cancer
- Development agreement with SAKK
- Large global market opportunity

4

## In- & out-licensing, partnering & M&A in oncology

- Cantrixil in-licensed early 2021 in ovarian cancer
- Discussions ongoing to acquire other promising assets
- Boutique investment firms driving process to partner or out-license Animal Health cancer assets and XR-17™

# Apealea® – an improved treatment option in ovarian cancer

1

Solvent-free IV formulation of paclitaxel

- No polyoxyethylated castor oil or dehydrated alcohol
- No glucocorticosteroids required pre-medication
- Shorter infusion and overall 'chair' time

Approved in EU for treatment of first relapse ovarian cancer<sup>1</sup>

Targeting patients unable to tolerate solvent-based paclitaxel






**apealea®**  
paclitaxel (micellar)

**Taxol®**

**Abraxane®**  
nanoparticle albumin bound paclitaxel

**Lipusu®**

**Genexol-PM®**  
Korea


Company	 oasmia	 Bristol Myers Squibb™	 Celgene	 LUYE PHARMA	 samyang Biopharm
Indication	Ovarian Cancer	Ovarian Cancer Breast Cancer NSCLC	Breast Cancer	Ovarian Cancer Breast Cancer NSCLC	Ovarian Cancer Breast Cancer NSCLC
Infusion Solution	Micellar Solution	Emulsion	Colloidal Suspension	Liposome	Micellar Solution
Particle Size	25nm	10-22nm	130nm	400nm	~25nm
Excipient	XR-17™	Cremophor EL	Human Albumin	Lecithin/Cholesterol	PEG-PDLLA
Dose	250mg/m <sup>2</sup>	175mg/m <sup>2</sup>	260mg/m <sup>2</sup>	175mg/m <sup>2</sup>	260mg/m <sup>2</sup>
Ratio (Excipient : API)	1.3:1.0	88.0:1.0	9.0:1.0	-	5.0:1.0
Infusion Time	1h	3h	<1h	3h	0.5h
Pre-medication	Not mandatory	Yes	No	Yes	No
Hypersensitivity	No	Yes	No	Yes	No

 elevator  
therapeutics

 HLB

**Global commercialization agreement with US-based Elevar Therapeutics, subsidiary of South Korea's HLB, worth up to \$698m + royalties**

# Maximizing Apealea® – leveraging our global agreement with Elevar



# XR-17™ – tackling poor drug solubility

## POOR API<sup>1</sup> SOLUBILITY

Major challenge in  
drug development

Critical to drug  
bioavailability

## AFFECTS c.40% OF APPROVED DRUGS<sup>2</sup>

70-90% of pipeline  
drugs classed as  
poorly soluble<sup>2</sup>

Leading cause of  
project  
termination

## IMPLICATED IN SERIOUS ADVERSE EVENTS

Solubility enhancers  
can cause SAEs and  
/ or require use of  
further drugs

Accepted trade off  
in cancer therapy


## A SIGNIFICANT PROBLEM FOR PATIENTS AND PHARMA COMPANIES

\$180 bn  
SPENT ON  
PHARMA R&D  
EVERY YEAR <sup>3</sup>

69%  
OF DRUGS  
FAIL DUE TO  
LOW  
SOLUBILITY <sup>3</sup>

1) API = Active Pharmaceutical Ingredient - the ingredient in a pharmaceutical drug that is biologically active  
2) Nikolakakis & Partheniadis  
3) GlobalData

# XR-17™ – targeting improved safety and efficacy



- ✓ High drug delivery capability
- ✓ Shorter infusion time<sup>1,2</sup>
- ✓ Superior solubility
- ✓ Enhanced API bioavailability
- ✓ Validated safety in cancer <sup>1</sup>
- ✗ No or limited need for pre-medication<sup>1</sup>
- ✗ No alcohol, Crem. EL, Polys.80, human albumin

Cancers:

- ✓ Ovarian
- ✓ Prostate
- ✓ Bladder
- ✓ Lung
- ✓ Breast
- ✓ Other TAs & animal health



# Expanding our technologies



**Collaboration with the Karolinska Institutet initiated to further explore the biological potential of Oasmia's proprietary drug delivery platform**

# Docetaxel micellar – phase 1b in prostate cancer to begin H1 2021

- Phase 1b trial to be initiated by SAKK (Swiss Group for Clinical Cancer Research)
- Protocol evaluation review underway
  - Docetaxel approved for wide range of solid malignancies
  - Standard of care for advanced prostate cancer
  - Docetaxel micellar uses XR-17™ to enable IV administration of docetaxel without solubility enhancers




**1 in 7**  
men will be  
diagnosed with  
prostate  
cancer



**1.3m**  
newly diagnosed  
in 2018<sup>1</sup>

## Actively seeking in-licensing opportunities & collaborations

- We want to in-license oncology products from pre-clinical up to late Phase 3 development



- We're also pursuing collaborations to support partners' R&D and overcome solubility challenges

## Cantrixil – building critical mass in our oncology pipeline

- Global rights to drug candidate Cantrixil (INN/TRX-E002-1) licensed from Kazia Therapeutics Limited (ASX:KZA)
- Builds on Oasmia's proven development and regulatory expertise in ovarian cancer
- Evaluating potential for synergies with Apealea® and XR-17™ solubility technology platform
- First in planned series of “string of pearls” acquisitions & in-licensing deals

## Cantrixil – first-in-class ovarian cancer therapy with strong Phase 1 data

- Tubulin-binding small molecule with potent cytotoxicity against CD 44+ ovarian cancer stem cells, ovarian somatic cancer cells (CD 44+), both resistant to standard chemotherapies
  - Potential to improve outcome in relapsed ovarian cancer
  - Favorable safety profile in I.P. use
  - Favorable PK profile for combination with standard of care agents
- Orphan drug designation from US FDA
- Composition of matter patent protection to 2035
- Possible opportunities in other CD 44+ cancer such as bladder
- Focus on securing product supplies and validating Phase II trial design for 2022 initiation

# A rapidly growing clinical-stage portfolio

Product	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration / approval	Commercial Launch	Geography	
Human Health Portfolio									
Apealea® / Paclical® (paclitaxel)	Ovarian cancer	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div>&lt;</div>							

## Focusing resources – strong cash position & reduced cash burn rate<sup>1,2</sup>

- Cash and cash equivalents & short-term investments TSEK 287,405 (325,658)
- Consolidated net sales TSEK 482 (565)
- Operating profit/loss TSEK -131,493 (-117,256)
  - Cash burn to reduce over the next two years to 10-12 MSEK per month
- Net profit/loss after tax TSEK -140,270 (-93,263)
- Earnings per share SEK -0.31 (-0.36)

1. Figures in brackets show outcomes for the corresponding period of the previous financial year.
2. From January 1, 2021, Oasmia will switch to calendar-year financial reporting. This year-end report therefore covers an abbreviated financial year for the period May 1 – December 31, 2020. The third quarter is abbreviated to cover the period November 1 - December 31, 2020. The comparative figures for the previous year report the same periods in 2019.

# The right team for success



**FRANCOIS MARTELET,**  
**M.D., Master's Degree Business**  
*Chief Executive Officer*



**FREDRIK JÄRRSTEN\***  
*Chief Finance Officer*



**DR HEIDI B. RAMSTAD,**  
**M.D.**  
*Chief Medical Officer*



**REINHARD KOENIG, M.D.**  
*Acting Chief Scientific Officer*



**ELIN TRAMPE, M.A.**  
*Chief Technical Officer*



**PETER SELIN, B.Sc.**  
*Chief Business Officer*



**ANDERS HÄRFSTRAND,**  
**M.D., PhD.**  
*Non-executive Chairman*



**HEGE HELLSTRÖM, B.A.**  
*Board Member*



**PETER ZONABEND,**  
**LL.M, EMLE**  
*Board Member*



**BIRGIT STATTIN**  
**NORINDER, M.Sc.**  
*Board Member*



## Sustained transformation & delivery since March 2020



# Looking ahead – multiple catalysts to drive near-term value

## Potential near- and mid-term value drivers

- Apealea® - partnering by Elevar in key territories; milestone payments & royalties
- Docetaxel micellar - Phase 1b initiation by SAKK
- Cantrixil – trial design, KOL recruitment and supply organization for Phase 2 (2022)
- XR-17™ technology platforms – further expansion incl. combination therapy proof of concept
- XR-17™ & Animal Health assets – partnering agreements
- Continued M&A and in-licensing to build critical mass in oncology

# Delivering on our four-pillar strategy for growth

1

Execute on Apealea®  
global partnership  
with Elevar



2

Enhancement &  
partnering of  
technology platforms



3

Clinical development  
of Docetaxel  
micellar



4

In- & out-licensing,  
partnering & M&A  
in oncology





# Thank you!

**Oasmia Pharmaceutical AB (STO: OASM)**

Vallongatan 1  
752 28 Uppsala  
Sweden



+46 018-50 54 40



[IR@oasmia.com](mailto:IR@oasmia.com)



[www.oasmia.com](http://www.oasmia.com)



[www.linkedin.com/company/oasmia-pharmaceutical-ab](https://www.linkedin.com/company/oasmia-pharmaceutical-ab)



[www.twitter.com/Oasmia](https://www.twitter.com/Oasmia)